Virtual biotechnology firm Tarix Pharmaceuticals Ltd. has won orphan drug designation from the U.S. Food and Drug Administration for TXA127, its drug target used in the engraftment of stem cell transplant patients. The designation applies to the treatment of TXA127 to Myelodysplastic Syndromes, diseases of the blood and bone marrow.
The drug candidate is intended to help patients recover their stem cell population, without risking infection or bleeding following a stem cell transplant. The peptide TXA127 prompts an increase in all formed cells in the blood.
TXA127 is currently in a Phase 2 clinical trial to test the safety and efficacy of platelet recovery in patients with Hodgkin lymphoma, non-Hodgkin lymphoma or multiple myeloma. It is also planned for two clinical trials in cord blood transplantation,
On its website, Tarix lists Brookline as the location of its main contact, CEO Rick Franklin. The company licenses its technology from the University of Southern California, and it is incorporated in the Mediterranean country of Cyprus, Franklin said.